2019 Agenda

Cambridge Healthtech Institute’s 14th Annual

Neurotech Investing and Partnering Conference

Advancing Neurotechnology through Investment and Collaboration

May 21-22, 2019

The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.

Preliminary Agenda

State of the Neurotechnology Industry
Guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices and neurodiagnostics.
Speakers to be Announced

Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: To be Announced
Laura Tadvalkar, PhD, Senior Associate, MP Health Partners
Deanna Belsky, PhD, Associate, Dolby Family Ventures
Maria Shepherd, Mass Medical Angels

Treatments for Alzheimer’s and Cognitive Disorders
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?

Moderator To be Announced
Zach Malchano, CEO, Cognito
Martin Tolar, MD, PhD, CEO, Alzheon



Developments on the Horizon for Pain and Epilepsy
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain. Hear from leading companies on their approaches.
Speakers to be Announced

Internal and External Research and Development
Pharmaceutical and Device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in-house or partnered. This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes, and platform companies.
Moderator: Michael Kandra, Director Business Development, Allen Brain Institute
Eric Schaeffer, Senior Director of Neuroscience Innovation Johnson & Johnson Innovation
Pierandrea Muglia, Vice President & Head Neuroscience Discovery Medicine, UCB Pharma

Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner.
Moderator: Christine de los Reyes, Vice President Strategic Planning & Business Development, Alopexx Enterprises
Murali Gopalakrishnan, Head of Neuroscience Search and Evaluation, AbbVie
Atsushi Hashimoto, Director Business Development, Mitsubishi Tanabe Pharma

Parkinson’s and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” period especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This session will explore how disease modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.
Speakers to be Announced

Next Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.
Moderator: Manuel Lopez Figueroa, Managing Director, Bay City Capital
David Baker, CEO, Vallon Pharma

Frontiers in Neurotechnology
In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets. Closed loop systems create the promise of reduced side effects and more targeted treatment. New technology is yielding benefits in delivery of therapeutics to brain. This session will preview of next generation products and companies in neurotechnology.
Speakers to be Announced

Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntington’s, and more.
Speakers to be Announced

For more details on the conference, please contact:
Carla M. Lema Tome, MBA, PhD

Conference Producer

Cambridge Healthtech Institute

Phone: 321.626.9558
Email: clematome@cambridgeinnovationinstitute.com


For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781.247.6286
Email: reymael@healthtech.com



Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag

Register Early for Maximum Savings